SVT-40776 in Patients Suffering From Overactive Bladder Syndrome.

Trial Profile

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2011

At a glance

  • Drugs Tarafenacin (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Additional lead trial centre and actual initiation date (Sep 2006) identified as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top